Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

218
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
218
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

558
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
558
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

622
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
622
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

239
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
239
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

505
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
505

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Self-assembled multifunctional polymeric micelles for tumor-specific bioimaging and synergistic chemo-phototherapy of cancer" [Int. J. Pharm. 602 (2021) 120651].

International journal of pharmaceutics·2026
Same author

K<sup>+</sup>/Cu<sup>2+</sup> Co-chelated diastereoselective Friedel-Crafts reaction with chiral <i>N</i>-sulfinyl ketimines for the facile synthesis of chiral bisindoles and their cytotoxicity.

RSC advances·2026
Same author

Enhanced carbon-nitrogen coupling and reduced organic carbon stability in the Liaohe River estuary wetland, China, induced by human activity.

Environmental research·2026
Same author

A structure-process hydrological connectivity framework for estuarine wetland management: Case study of a typical Estuary in Northern China.

Journal of environmental management·2026
Same author

NaHMDS/B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>-promoted diastereoselective Friedel-Crafts alkylation of indoles/pyrroles with <i>N-tert</i>-butanesulfinylimines: towards the asymmetric synthesis of bisindole alkaloid Calcicamide B.

RSC advances·2025
Same author

Advancing antifungal therapy: exploring targeted CFW-PEc-enhanced ethosomal formulations of amphotericin B against cryptococcal pneumonia.

Microbiology spectrum·2025

Related Experiment Video

Updated: Aug 14, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Programmed pH-responsive core-shell nanoparticles for precisely targeted therapy of ulcerative colitis.

Guangshuai Zhang1, Wen Han1, Peixu Zhao1

  • 1Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China. graham_pharm@aliyun.com.

Nanoscale
|January 10, 2023
PubMed
Summary

New core-shell nanoparticles precisely target ulcerative colitis (UC) inflammation sites in the colon. This targeted drug delivery system, using pH-sensitive materials, improves curcumin accumulation and reduces side effects for effective UC therapy.

More Related Videos

Synthesis of Core-shell Lanthanide-doped Upconversion Nanocrystals for Cellular Applications
13:51

Synthesis of Core-shell Lanthanide-doped Upconversion Nanocrystals for Cellular Applications

Published on: November 10, 2017

15.4K
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

8.9K

Related Experiment Videos

Last Updated: Aug 14, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Synthesis of Core-shell Lanthanide-doped Upconversion Nanocrystals for Cellular Applications
13:51

Synthesis of Core-shell Lanthanide-doped Upconversion Nanocrystals for Cellular Applications

Published on: November 10, 2017

15.4K
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

8.9K

Area of Science:

  • Nanotechnology
  • Materials Science
  • Pharmacology

Background:

  • Current pH-responsive nanotherapeutics for ulcerative colitis (UC) lack site-specific targeting within the colon.
  • This leads to suboptimal drug accumulation at inflamed lesions and potential off-target side effects.

Purpose of the Study:

  • To develop core-shell nanoparticles for precise, pH-triggered delivery of curcumin to inflamed colon sites.
  • To evaluate the anti-inflammatory efficacy and targeted accumulation of these novel nanoparticles in a UC model.

Main Methods:

  • Fabrication of core-shell nanoparticles (CNs@EPO@L100) by coating nano-sized curcumin with pH-sensitive polymers Eudragit® EPO and L100.
  • Assessment of programmed pH-responsive drug release in vitro.
  • Evaluation of anti-inflammatory activity and colon tissue accumulation in a mouse model of UC.

Main Results:

  • The developed CNs@EPO@L100 demonstrated programmed pH-responsive drug release.
  • Enhanced in vitro anti-inflammatory effects were observed.
  • Significantly improved accumulation at inflamed colon sites and amelioration of UC symptoms in mice after oral administration.

Conclusions:

  • Core-shell nanoparticle design enables programmed pH-responsive drug release for targeted UC therapy.
  • This strategy offers a promising approach to enhance therapeutic precision and minimize side effects in ulcerative colitis treatment.